Skip to main content
UniHealth

Doctor search

Paul Yien Kwo, MD

Gastroenterology · Stanford

NPI 1578527008

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Offices
7

Offices

7 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Clovis Community Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kwo’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G145613 · Current

Licensed to practise in California · since 2016 · expires 2027-12-31 · Wayne State University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend it
    Overall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center

Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Clovis Community Medical Center
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.7 (12.1 to 17.7) · 421 casesWorseJan 2024 – Dec 2024
Clostridium Difficile (C.Diff)Infections0.692BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.97 (0.04 to 1.89) · 1,840 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.16 (0.86 to 1.45)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths217.06 (167.45 to 266.67) · 84 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.4 · 69 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths9.1 · 165 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths13.4 · 161 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths14 · 507 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths17.6 · 798 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 336 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.1 · 3,771 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.19 (0 to 0.39) · 8,649 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.08 to 0.46) · 9,146 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.46 (1.47 to 5.45) · 1,654 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2.19 (0.61 to 3.78) · 387 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.18 (0.7 to 3.66) · 1,578 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths13.47 (7.08 to 19.87) · 374 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.99 (1.37 to 8.61) · 379 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.58 (0.13 to 3.04) · 405 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.8 (0.23 to 1.38) · 8,198 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.2 · 90 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.651No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.922No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.449No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.509No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.3 · 210 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits23 · 702 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-1.5 · 152 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits58.4 · 556 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits18 · 769 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.8 · 802 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.5 (4 to 7.4) · 421 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.2 · 91 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 93 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 200 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.8 to 15.6) · 2,398 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.6 to 1.1) · 720 casesNo differentJan 2024 – Dec 2024

What patients said (441 patients answered, 26% of those asked)

Patient survey stars by topic at Clovis Community Medical Center
Cleanliness4
Nurse communication3
Doctor communication2
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Clovis Community Medical Center
Room was "always" clean80%
Nurses "always" communicated well75%
Doctors "always" communicated well75%
Staff "always" explained61%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand69%
Doctors "always" listened carefully73%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)72%
Staff "always" explained new medications74%
Nurses "always" explained things so they could understand71%
Nurses "always" listened carefully71%
Nurses "always" treated them with courtesy and respect83%
"Always" quiet at night52%
"YES", patients would definitely recommend the hospital80%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$60,689

Medicare paid this office $60,689 for 388 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Short return visit (20+ min)197$20,610$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes37$8,824$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$4,190$105
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes26$3,035$117
Return visit (30+ min)25$2,960$102
See all 15 services
Every Original Medicare service billed
Short return visit (20+ min)197$20,610$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes37$8,824$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$4,190$105
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes26$3,035$117
Return visit (30+ min)25$2,960$102
Removal of polyps or growths of large bowel using an endoscope with mechanical snare12$2,836$236
New patient visit (30+ min)36$2,580$72
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope19$1,968$98
New patient visit (45+ min)13$1,409$108
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope11$1,105$100
Biopsy of large bowel using a flexible endoscope13$1,055$81
Biopsy of large bowel using a flexible endoscope11$1,020$93
Short return visit19$830$41
Measurement of liver stiffness80$697$9
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's42$608$14

Procedures Medicare counted

Procedure volume Medicare published
Colonoscopy11More than 41% of doctors who do this
Upper gastrointestinal (GI) endoscopy for acid reflux35More than 58% of doctors who do this

Who their Medicare patients are

388 Original Medicare patients in 2024. Average age 70 · Under 65 17% · 85 and older 6% · Women 55% · Also on Medicaid 39% · Health risk score 2.34. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.

Conditions among them: High blood pressure 74% · Diabetes 39% · Chronic kidney disease 31% · Coronary heart disease 30% · Heart failure 20% · Depression 20% · Atrial fibrillation 19% · Cancer 15% · COPD 15% · Stroke 7% · Dementia 6%.

The office billed $423,343, Medicare allowed $79,511 and paid $60,689; for 849 services of 29 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024388849702.34$423,343$60,689
2023383843692.38$332,010$58,003
2022326733702.31$339,149$49,213
2021271646682.48$302,879$46,675
2020299716672.59$320,477$45,622
2019255652672.52$217,340$43,533
2018240642672.81$279,598$45,719
2017162413652.77$134,730$29,963
2016460950642.64$206,731$51,751
20154741,134632.54$261,501$62,767
20145051,259632.28$282,401$70,661
20134791,310632.58$292,286$74,089

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 12 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes51$14,702$72
Short return visit (20+ min)166$12,562$57
New patient visit (30+ min)65$5,270$81
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$4,606$110
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes26$3,103$119
Short return visit (20+ min)27$2,870$55
Hospital discharge day management, 30 minutes or less21$1,746$76
New patient visit (45+ min)12$1,722$144
Return visit (30+ min)11$1,277$91
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes25$691$28
Measurement of liver stiffness71$648$9
Telehealth originating site facility fee14$303$22

2022: 9 services

Original Medicare services billed in 2022
Short return visit (20+ min)145$12,675$55
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes36$7,042$64
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$4,297$93
New patient visit (45+ min)30$3,730$124
Short return visit (20+ min)27$3,418$57
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes23$2,821$123
New patient visit (30+ min)20$1,867$93
Measurement of liver stiffness65$590$9
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes17$520$31

2021: 9 services

Original Medicare services billed in 2021
Short return visit (20+ min)137$14,069$60
New patient visit (45+ min)38$5,501$145
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes36$4,570$66
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes27$3,406$126
Short return visit (20+ min)25$3,152$54
Return visit (30+ min)15$1,546$97
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope11$1,173$107
Measurement of liver stiffness49$421$8
Telehealth originating site facility fee16$335$21

2020: 11 services

Original Medicare services billed in 2020
Short return visit (20+ min)146$11,628$45
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes45$7,788$67
New patient visit (45+ min)39$4,513$116
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes27$3,554$127
Short return visit (20+ min)27$2,093$44
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$1,442$96
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope14$1,429$102
Return visit (30+ min)11$873$79
Telephone medical discussion with physician, 11-20 minutes16$871$54
Telehealth originating site facility fee34$812$21
Measurement of liver stiffness23$294$12

2019: 9 services

Original Medicare services billed in 2019
Short return visit (20+ min)123$9,380$43
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes38$7,862$65
New patient visit (45+ min)54$6,557$121
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes21$2,678$122
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$2,415$93
Short return visit (20+ min)25$2,231$45
Return visit (30+ min)21$1,667$72
Return visit (30+ min)18$1,344$71
Measurement of liver stiffness28$320$11

2018: 14 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes60$11,035$65
Short return visit (20+ min)71$4,244$43
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes33$4,141$122
Short return visit (20+ min)62$3,819$48
New patient visit (45+ min)30$3,747$125
Removal of polyps or growths of large bowel using an endoscope with mechanical snare11$2,449$223
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$2,245$94
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope23$2,228$97
New patient visit (45+ min)18$1,624$90
Return visit (30+ min)15$1,342$71
Hospital discharge day management, 30 minutes or less19$1,270$67
Biopsy of large bowel using a flexible endoscope11$834$76
Measurement of liver stiffness13$166$13
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito19$91$5

2017: 8 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes32$6,404$65
New patient visit (45+ min)53$5,764$109
Short return visit (20+ min)62$3,833$44
Return visit (30+ min)25$2,398$71
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$2,244$93
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,578$121
Long return visit (40+ min)12$1,098$91
Measurement of liver stiffness23$251$11

2016: 10 services

Original Medicare services billed in 2016
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes58$12,069$54
Short return visit (20+ min)216$9,222$33
Short return visit (20+ min)86$5,126$47
Return visit (30+ min)70$4,665$50
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes43$4,600$102
New patient visit (45+ min)29$2,440$84
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope16$1,536$90
Hospital discharge day management, 30 minutes or less26$1,455$52
Long return visit (40+ min)16$1,294$81
Return visit (30+ min)14$1,115$74

2015: 13 services

Original Medicare services billed in 2015
Short return visit (20+ min)264$13,153$35
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes45$11,697$55
Short return visit (20+ min)119$7,111$41
Return visit (30+ min)69$5,329$55
Removal of polyps or growths of large bowel using an endoscope with mechanical snare16$3,718$232
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes31$3,349$101
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope30$2,806$88
New patient visit (45+ min)26$2,462$95
Biopsy of large bowel using a flexible endoscope17$1,855$109
Hospital discharge day management, 30 minutes or less25$1,385$55
Return visit (30+ min)17$1,196$63
Long return visit (40+ min)12$1,016$85
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes15$565$30

2014: 13 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes60$14,157$55
Short return visit (20+ min)267$13,333$36
Short return visit (20+ min)117$8,060$46
Return visit (30+ min)96$7,831$56
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope50$4,259$84
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes35$4,165$104
Removal of polyps or growths of large bowel using an endoscope with mechanical snare11$2,556$232
New patient visit (45+ min)18$1,771$98
Biopsy of large bowel using a flexible endoscope13$1,724$133
Hospital discharge day management, 30 minutes or less29$1,698$55
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes11$1,576$79
Return visit (30+ min)17$1,052$50
Short return visit23$477$18

2013: 13 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes79$17,514$51
Return visit (30+ min)132$10,867$54
Short return visit (20+ min)223$10,628$34
Short return visit (20+ min)105$7,130$48
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope44$4,352$93
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes38$3,874$97
Biopsy of large bowel using a flexible endoscope16$2,425$152
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,114$151
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$1,994$77
Hospital discharge day management, 30 minutes or less34$1,982$54
New patient visit (45+ min)20$1,821$91
Long return visit (40+ min)18$1,295$68
Return visit (30+ min)21$1,192$48

Medicaid work

$23,576 in 2024

Medicaid paid $23,576 for 420 billed services this clinician did in 2024, up to 34 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)167$14,969
Short return visit (20+ min)162$6,011
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES60$1,893
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES31$704
Medicaid work by year
2024420434$23,576
2023673442$16,525
2022484436$13,324
2021315232$8,075
2020398236$11,220
2019292230$6,922
2018233230$6,445
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES315$6,898
Short return visit (20+ min)254$5,701
Return visit (30+ min)74$2,772
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES30$1,154

2022

Largest Medicaid services in 2022
Short return visit (20+ min)359$8,516
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES85$3,188
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES28$1,502
Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report12$118

2021

Largest Medicaid services in 2021
Short return visit (20+ min)253$6,308
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES62$1,768

2020

Largest Medicaid services in 2020
Short return visit (20+ min)282$6,826
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES116$4,393

2019

Largest Medicaid services in 2019
Short return visit (20+ min)257$5,476
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES35$1,446

2018

Largest Medicaid services in 2018
Short return visit (20+ min)197$5,134
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES36$1,311

Drugs they prescribed that Part D paid

$367,734

Pharmacies billed $367,734 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,000) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.

851 generic and 149 brand-name prescriptions · $367,734 in drug cost · 47 antibiotic prescriptions to 13 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Xifaxan34$110,724$3,257
Vemlidy63$94,556$1,501
Mycophenolate Mofetil87$16,844$194
Entecavir62$12,791$206
Mycophenolic Acid12$9,159$763
See all 22 drugs
Every Part D drug this clinician prescribed
Xifaxan34$110,724$3,257
Vemlidy63$94,556$1,501
Mycophenolate Mofetil87$16,844$194
Entecavir62$12,791$206
Mycophenolic Acid12$9,159$763
Ursodiol73$8,302$114
Tacrolimus62$7,289$118
Cyclosporine Modified37$6,224$168
Tenofovir Disoproxil14$3,622$259
Lansoprazole24$2,262$94
Spironolactone41$515$13
Peg 3350-Electrolyte24$465$19
Lactulose16$443$28
Fludrocortisone Acetate34$355$10
Carvedilol65$337$5
Pantoprazole39$324$8
Esomeprazole Magnesium12$246$21
Potassium Chloride19$242$13
Furosemide33$167$5
Omeprazole17$151$9
Prednisone35$112$3
Amlodipine Besylate17$59$3

Year by year

Part D prescribing by year
20241,0001640% (0)15%$367,734
2023810130None11%$209,912
20227581180% (0)18%$256,034
20216791080% (0)23%$335,275
2020670121None25%$503,304
2019559112NoneNone$336,415
2018400106NoneNone$651,155
2017738193None24%$842,770
20163,5203601% (46)None$4,330,715
20154,0223842% (84)28%$9,978,656
20144,3293532% (92)None$9,403,774
20133,6792842% (69)28%$1,057,929

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 23 drugs

Part D drugs prescribed in 2023
Xifaxan20$64,900$3,245
Vemlidy26$42,887$1,650
Tacrolimus50$11,503$230
Ursodiol50$11,368$227
Mycophenolate Mofetil79$11,203$142
Entecavir52$9,981$192
Mycophenolic Acid11$4,894$445
Cyclosporine Modified31$4,717$152
Lansoprazole13$1,218$94
Azathioprine20$1,211$61
Spironolactone31$1,034$33
Fluconazole12$810$68
Pantoprazole44$792$18
Lactulose16$662$41
Fludrocortisone Acetate34$546$16
Carvedilol27$272$10
Amlodipine Besylate24$257$11
Peg 3350-Electrolyte12$236$20
Prednisone29$233$8
Metoprolol25$218$9
Furosemide25$213$9
Propranolol14$189$14
Sulfamethoxazole-Trimethoprim13$65$5

2022: 23 drugs

Part D drugs prescribed in 2022
Xifaxan25$74,486$2,979
Vemlidy30$43,852$1,462
Sirolimus21$18,229$868
Entecavir49$18,000$367
Ozempic13$14,415$1,109
Mycophenolic Acid18$12,898$717
Ursodiol33$10,234$310
Mycophenolate Mofetil50$6,056$121
Tacrolimus37$5,674$153
Cyclosporine Modified11$3,072$279
Valganciclovir12$2,258$188
Spironolactone65$1,861$29
Bupropion Xl11$511$46
Furosemide67$354$5
Pantoprazole28$307$11
Peg 3350-Electrolyte16$295$18
Fludrocortisone Acetate16$209$13
Carvedilol27$169$6
Sulfamethoxazole-Trimethoprim13$141$11
Metoprolol13$133$10
Amlodipine Besylate31$130$4
Metoprolol17$121$7
Prednisone19$80$4

2021: 17 drugs

Part D drugs prescribed in 2021
Xifaxan36$109,564$3,043
Vemlidy43$55,380$1,288
Entecavir39$23,568$604
Mycophenolic Acid12$12,550$1,046
Mycophenolate Mofetil42$6,339$151
Tacrolimus24$4,942$206
Cyclosporine Modified22$4,671$212
Ursodiol12$2,698$225
Lactulose27$1,867$69
Spironolactone77$1,760$23
Potassium Chloride14$1,117$80
Furosemide78$501$6
Prednisone25$139$6
Amlodipine Besylate20$130$7
Fludrocortisone Acetate11$126$11
Carvedilol12$113$9
Bupropion Xl12$99$8

2020: 15 drugs

Part D drugs prescribed in 2020
Xifaxan27$68,605$2,541
Vemlidy54$64,828$1,201
Mycophenolic Acid14$17,184$1,227
Entecavir48$15,759$328
Mycophenolate Mofetil36$8,643$240
Ursodiol17$4,386$258
Cyclosporine Modified14$3,052$218
Lactulose39$1,582$41
Spironolactone54$1,416$26
Furosemide71$456$6
Omeprazole31$272$9
Bupropion Xl12$199$17
Carvedilol30$188$6
Prednisone19$155$8
Glipizide12$86$7

2019: 13 drugs

Part D drugs prescribed in 2019
Vemlidy37$50,624$1,368
Xifaxan21$47,002$2,238
Tacrolimus15$6,232$415
Mycophenolate Mofetil33$6,201$188
Entecavir61$5,432$89
Ursodiol12$4,367$364
Tenofovir Disoproxil13$2,622$202
Cholestyramine15$1,703$114
Spironolactone47$960$20
Lactulose25$863$35
Furosemide48$212$4
Prednisone19$115$6
Amlodipine Besylate14$56$4

2018: 9 drugs

Part D drugs prescribed in 2018
Vemlidy29$30,440$1,050
Ursodiol25$8,029$321
Entecavir15$3,973$265
Spironolactone26$1,076$41
Furosemide43$269$6
Peg 3350-Electrolyte16$238$15
Lactulose11$208$19
Omeprazole19$160$8
Sertraline11$62$6

2017: 22 drugs

Part D drugs prescribed in 2017
Epclusa19$483,148$25,429
Xifaxan15$29,696$1,980
Ursodiol55$18,439$335
Tacrolimus63$15,664$249
Viread14$15,159$1,083
Entecavir14$13,001$929
Prograf11$4,913$447
Mycophenolate Mofetil25$2,991$120
Neoral11$2,646$241
Azathioprine15$1,149$77
Omeprazole55$720$13
Cyclosporine Modified13$696$54
Lactulose15$552$37
Fludrocortisone Acetate27$492$18
Propranolol18$360$20
Spironolactone33$359$11
Pravastatin12$115$10
Furosemide27$111$4
Amlodipine Besylate17$108$6
Sertraline14$107$8
Pantoprazole13$103$8
Levothyroxine19$90$5

2016: 58 drugs

Part D drugs prescribed in 2016
Harvoni61$1,932,586$31,682
Sovaldi22$623,364$28,335
Epclusa14$342,104$24,436
Xifaxan161$314,978$1,956
Daklinza12$254,015$21,168
Ursodiol217$69,390$320
Tacrolimus402$65,874$164
Viread49$43,520$888
Cellcept16$41,810$2,613
Entecavir37$30,690$829
Mycophenolate Mofetil242$29,622$122
Lamivudine Hbv45$23,413$520
Sirolimus38$17,808$469
Prograf44$17,482$397
Truvada12$17,421$1,452
Mycophenolic Acid18$16,331$907
Lialda16$10,048$628
Nexium25$8,327$333
Ribavirin48$6,713$140
Balsalazide Disodium16$4,322$270
Cyclosporine Modified50$4,088$82
Lactulose96$3,959$41
Gengraf18$3,874$215
Neoral13$3,610$278
Omeprazole220$3,391$15
Azathioprine32$3,079$96
Spironolactone122$2,783$23
Amiloride46$2,219$48
Esomeprazole Magnesium16$1,666$104
Fludrocortisone Acetate82$1,582$19
Propranolol51$1,145$22
Furosemide172$829$5
Levothyroxine62$781$13
Escitalopram20$620$31
Pantoprazole43$612$14
Ondansetron14$608$43
Potassium Chloride23$533$23
Promethazine14$495$35
Amlodipine Besylate52$494$9
Metoprolol28$466$17
Warfarin41$421$10
Klor-Con M2022$385$17
Generlac14$371$27
Tamsulosin11$308$28
Tramadol20$297$15
Sertraline56$262$5
Metoprolol52$254$5
Sulfamethoxazole-Trimethoprim27$250$9
Carvedilol41$242$6
Famotidine21$234$11
Pravastatin13$203$16
Gabapentin14$202$14
Prednisone19$142$7
Ciprofloxacin22$141$6
Torsemide16$112$7
Trazodone19$101$5
Lisinopril20$97$5
Atenolol15$91$6

2015: 67 drugs

Part D drugs prescribed in 2015
Harvoni225$7,257,774$32,257
Sovaldi37$1,088,353$29,415
Daklinza17$395,716$23,277
Viekira Pak13$367,790$28,292
Xifaxan164$270,552$1,650
Ursodiol245$84,329$344
Tacrolimus346$72,174$209
Entecavir38$47,567$1,252
Viread64$41,398$647
Cellcept16$39,434$2,465
Sirolimus53$35,319$666
Mycophenolate Mofetil250$30,770$123
Prograf52$27,762$534
Lamivudine Hbv44$24,242$551
Ribavirin69$19,553$283
Truvada12$16,512$1,376
Nexium33$15,213$461
Rapamune16$13,882$868
Lialda13$8,336$641
Nuvigil12$7,523$627
Cyclosporine Modified54$6,516$121
Spironolactone165$4,241$26
Lactulose90$3,549$39
Balsalazide Disodium30$3,384$113
Azathioprine44$2,971$68
Ribasphere23$2,960$129
Omeprazole178$2,548$14
Fludrocortisone Acetate66$1,384$21
Amiloride21$1,279$61
Ondansetron25$1,180$47
Mirtazapine29$1,152$40
Klor-Con M2030$911$30
Furosemide218$853$4
Tamsulosin26$849$33
Synthroid25$799$32
Levothyroxine74$789$11
Pantoprazole59$771$13
Warfarin51$706$14
Pravastatin25$702$28
Escitalopram17$693$41
Propranolol30$662$22
Metoprolol28$525$19
Lansoprazole11$519$47
Amlodipine Besylate78$516$7
Hydroxyzine24$514$21
Sulfamethoxazole-Trimethoprim61$491$8
Metoprolol87$451$5
Valsartan-Hydrochlorothiazide15$439$29
Gabapentin24$417$17
Temazepam14$411$29
Generlac14$392$28
Potassium Chloride17$381$22
Tramadol44$376$9
Sertraline58$314$5
Oxycodone14$277$20
Doxepin14$253$18
Peg 3350-Electrolyte16$252$16
Carvedilol45$218$5
Prednisone24$196$8
Ciprofloxacin30$177$6
Promethazine17$164$10
Trazodone21$77$4
Lisinopril18$76$4
Citalopram Hbr11$67$6
Clopidogrel11$60$5
Atenolol12$48$4
Glipizide11$44$4

2014: 70 drugs

Part D drugs prescribed in 2014
Sovaldi198$5,685,932$28,717
Olysio71$1,613,795$22,730
Harvoni31$995,009$32,097
Xifaxan252$368,644$1,463
Tacrolimus309$84,583$274
Ursodiol244$65,694$269
Valcyte13$53,864$4,143
Baraclude29$49,172$1,696
Prograf70$45,875$655
Cellcept16$36,514$2,282
Viread44$36,102$820
Nexium70$32,002$457
Mycophenolate Mofetil172$28,760$167
Rapamune25$27,937$1,117
Lamivudine Hbv56$22,977$410
Entecavir13$22,405$1,723
Truvada12$15,748$1,312
Ribasphere90$15,248$169
Lialda20$14,774$739
Spironolactone215$6,156$29
Cyclosporine Modified33$5,916$179
Cyclosporine33$5,759$175
Sirolimus13$5,651$435
Ribavirin35$5,245$150
Gengraf13$4,585$353
Lactulose118$4,531$38
Omeprazole215$3,820$18
Creon15$3,574$238
Azathioprine82$3,040$37
Neoral11$2,434$221
Lansoprazole41$1,946$47
Amiloride24$1,607$67
Hydrocodone-Acetaminophen30$1,557$52
Fludrocortisone Acetate61$1,264$21
Metoprolol34$1,251$37
Furosemide234$1,081$5
Ondansetron16$983$61
Generlac19$931$49
Pravastatin47$885$19
Hydroxyzine13$783$60
Klor-Con M2038$779$20
Sertraline75$757$10
Potassium Chloride22$717$33
Levothyroxine68$713$10
Doxepin33$703$21
Synthroid24$670$28
Amlodipine Besylate54$628$12
Pantoprazole44$622$14
Sulfamethoxazole-Trimethoprim55$505$9
Propranolol45$476$11
Escitalopram30$461$15
Metoprolol58$450$8
Valacyclovir11$392$36
Oxycodone13$316$24
Promethazine11$303$28
Warfarin52$295$6
Prednisone36$283$8
Ciprofloxacin41$270$7
Gabapentin23$259$11
Carvedilol33$235$7
Fluoxetine18$232$13
Tramadol34$225$7
Citalopram Hbr29$171$6
Zolpidem15$162$11
Atorvastatin14$158$11
Ranitidine19$143$8
Clonidine17$139$8
Trazodone18$69$4
Lisinopril18$38$2
Atenolol12$0$0

2013: 61 drugs

Part D drugs prescribed in 2013
Xifaxan171$235,788$1,379
Nexavar11$83,436$7,585
Tacrolimus209$63,272$303
Ursodiol273$61,941$227
Baraclude22$42,055$1,912
Prograf59$40,333$684
Viread44$33,700$766
Cellcept16$33,545$2,097
Nexium77$26,673$346
Rapamune17$26,470$1,557
Mycophenolate Mofetil138$22,874$166
Epivir Hbv45$22,185$493
Opium Tincture11$6,683$608
Spironolactone205$6,639$32
Cyclosporine Modified22$6,165$280
Gengraf22$5,114$232
Omeprazole189$4,335$23
Cyclosporine12$3,548$296
Lactulose71$3,220$45
Azathioprine93$2,855$31
Escitalopram42$2,838$68
Neoral12$2,650$221
Lansoprazole32$2,164$68
Potassium Chloride26$1,839$71
Valacyclovir13$1,642$126
Metoprolol45$1,585$35
Klor-Con M2054$1,521$28
Generlac24$1,414$59
Furosemide220$1,312$6
Sertraline112$1,203$11
Fludrocortisone Acetate51$1,103$22
Pantoprazole58$921$16
Levothyroxine106$819$8
Propranolol69$757$11
Hydroxyzine12$746$62
Hydrocodone-Acetaminophen24$738$31
Gabapentin36$693$19
Enulose13$635$49
Quetiapine12$597$50
Sulfamethoxazole-Trimethoprim65$577$9
Venlafaxine13$440$34
Ondansetron14$417$30
Metoprolol57$403$7
Pravastatin34$374$11
Doxepin24$372$15
Clonidine25$341$14
Amlodipine Besylate33$332$10
Zolpidem45$326$7
Citalopram Hbr38$318$8
Triazolam13$293$23
Ranitidine16$248$15
Peg-3350 With Flavor Packs13$246$19
Warfarin27$201$7
Oxycodone13$190$15
Ciprofloxacin35$158$5
Carvedilol16$145$9
Tramadol17$141$8
Prednisone23$135$6
Trazodone17$94$6
Lisinopril19$68$4
Atenolol11$26$2

Money from drug and device companies

$24,686 in 2025

Industry payments by year
2025620$22,475$24,686
2024416$16,189$21,057
2023216$10,310$11,390
202239$15,309$15,622
202148$17,868$17,981
202057$22,460$22,460
2019836$33,652$36,829

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Novo NordiskNone$10,464
6 payments
  • Travel · 2025-06-24 · $233
  • Travel · 2025-06-24 · $307
  • Travel · 2025-06-24 · $28
  • Travel · 2025-06-24 · $327
  • Meals · 2025-06-24 · $150
  • Consulting · 2025-06-24 · $9,420
Gilead SciencesLivdelzi$4,986
7 payments
  • Consulting · 2025-08-27 · $4,040
  • Travel · 2025-08-27 · $58
  • Travel · 2025-08-27 · $58
  • Travel · 2025-08-27 · $36
  • Travel · 2025-07-29 · $304
  • Travel · 2025-07-28 · $350
  • Meals for Livdelzi · 2025-05-05 · $140
GlaxoSmithKlineNone$3,600
2 payments
  • Consulting · 2025-11-24 · $3,200
  • Consulting · 2025-03-25 · $400
Salix Pharmaceuticals a division of Bausch Health USXifaxan$2,621
3 payments
  • Meals for Xifaxan · 2025-11-08 · $131
  • Meals for Xifaxan · 2025-04-10 · $91
  • Consulting for Xifaxan · 2025-03-19 · $2,400
GenentechNone$2,415
1 payment
  • Consulting · 2025-01-23 · $2,415
AmgenUplizna$600
1 payment
  • Consulting for Uplizna · 2025-01-07 · $600
See all 20 published payments
Every published payment
GlaxoSmithKlineConsulting · 2025-11-24None$3,200
Salix Pharmaceuticals a division of Bausch Health USMeals · 2025-11-08Xifaxan$131
Gilead SciencesConsulting · 2025-08-27None$4,040
Gilead SciencesTravel · 2025-08-27None$58
Gilead SciencesTravel · 2025-08-27None$58
Gilead SciencesTravel · 2025-08-27None$36
Gilead SciencesTravel · 2025-07-29None$304
Gilead SciencesTravel · 2025-07-28None$350
Novo NordiskTravel · 2025-06-24None$233
Novo NordiskTravel · 2025-06-24None$307
Novo NordiskTravel · 2025-06-24None$28
Novo NordiskTravel · 2025-06-24None$327
Novo NordiskMeals · 2025-06-24None$150
Novo NordiskConsulting · 2025-06-24None$9,420
Gilead SciencesMeals · 2025-05-05Livdelzi$140
Salix Pharmaceuticals a division of Bausch Health USMeals · 2025-04-10Xifaxan$91
GlaxoSmithKlineConsulting · 2025-03-25None$400
Salix Pharmaceuticals a division of Bausch Health USConsulting · 2025-03-19Xifaxan$2,400
GenentechConsulting · 2025-01-23None$2,415
AmgenConsulting · 2025-01-07Uplizna$600
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $21,057

Payments by company in 2024
Novo NordiskNone$14,480
10 payments
  • Meals · 2024-09-19 · $149
  • Travel · 2024-09-19 · $598
  • Travel · 2024-09-19 · $463
  • Travel · 2024-09-19 · $222
  • Meals · 2024-04-13 · $188
  • Travel · 2024-04-13 · $666
  • Consulting · 2024-04-13 · $9,999
  • Travel · 2024-04-13 · $1,879
  • Travel · 2024-04-13 · $27
  • Travel · 2024-04-13 · $289
Gilead SciencesVemlidy$6,401
3 payments
  • Consulting for Vemlidy · 2024-12-19 · $6,190
  • Meals for Livdelzi · 2024-11-16 · $145
  • Meals for Vemlidy · 2024-06-06 · $66
Exact SciencesNone$126
2 payments
  • Meals · 2024-04-05 · $108
  • Meals · 2024-03-22 · $19
Novo Nordisk ASNone$50
1 payment
  • Meals · 2024-11-19 · $50

2023: $11,390

Payments by company in 2023
Gilead SciencesVemlidy$10,090
15 payments
  • Consulting for Vemlidy · 2023-12-19 · $3,320
  • Meals · 2023-11-11 · $125
  • Travel for Epclusa · 2023-07-26 · $18
  • Consulting for Epclusa · 2023-06-28 · $1,690
  • Meals for Epclusa · 2023-06-24 · $20
  • Travel for Epclusa · 2023-06-22 · $40
  • Meals for Epclusa · 2023-06-22 · $117
  • Travel for Vemlidy · 2023-03-08 · $72
  • Consulting for Vemlidy · 2023-02-08 · $2,650
  • Consulting · 2023-01-27 · $1,350
  • Travel for Vemlidy · 2023-01-25 · $85
  • Meals · 2023-01-25 · $124
  • Meals · 2023-01-25 · $40
  • Travel for Vemlidy · 2023-01-24 · $198
  • Travel for Vemlidy · 2023-01-24 · $241
AbbvieNone$1,300
1 payment
  • Consulting · 2023-08-25 · $1,300

2022: $15,622

Payments by company in 2022
Gilead SciencesEpclusa$7,023
6 payments
  • Consulting · 2022-12-08 · $2,980
  • Meals · 2022-11-05 · $49
  • Meals · 2022-11-05 · $121
  • Consulting for Epclusa · 2022-06-25 · $1,780
  • Meals for Epclusa · 2022-03-12 · $65
  • Consulting · 2022-03-08 · $2,029
Mallinckrodt Hospital ProductsNone$5,799
2 payments
  • Consulting · 2022-07-21 · $5,720
  • Meals · 2022-06-22 · $79
GlaxoSmithKlineNone$2,800
1 payment
  • Consulting · 2022-12-20 · $2,800

2021: $17,981

Payments by company in 2021
Gilead SciencesNone$6,884
3 payments
  • Meals · 2021-10-24 · $114
  • Consulting · 2021-10-19 · $4,400
  • Consulting · 2021-05-26 · $2,370
Mallinckrodt Hospital ProductsNone$6,568
2 payments
  • Consulting · 2021-10-19 · $3,575
  • Consulting · 2021-06-28 · $2,993
EisaiLenvima$2,580
1 payment
  • Consulting for Lenvima · 2021-11-18 · $2,580
AbbVieMavyret$1,950
2 payments
  • Consulting for Mavyret · 2021-12-20 · $1,200
  • Consulting for Mavyret · 2021-05-19 · $750

2020: $22,460

Payments by company in 2020
Janssen Research & DevelopmentNone$8,750
1 payment
  • Consulting · 2020-04-06 · $8,750
Gilead SciencesEpclusa$6,160
2 payments
  • Consulting for Epclusa · 2020-11-02 · $2,710
  • Consulting · 2020-10-26 · $3,450
Mallinckrodt Hospital ProductsNone$3,150
1 payment
  • Consulting · 2020-12-16 · $3,150
AbbVieMavyret$2,400
2 payments
  • Consulting for Mavyret · 2020-12-11 · $1,200
  • Consulting for Mavyret · 2020-06-16 · $1,200
Merck Sharp & DohmeSch-018908 - Ribavirin$2,000
1 payment
  • Consulting for Sch-018908 - Ribavirin · 2020-06-17 · $2,000

2019: $36,829

Payments by company in 2019
Ferring PharmaceuticalsNone$13,181
8 payments
  • Consulting · 2019-07-02 · $12,600
  • Meals · 2019-05-16 · $69
  • Travel · 2019-05-16 · $36
  • Meals · 2019-05-16 · $22
  • Meals · 2019-05-15 · $89
  • Travel · 2019-05-14 · $299
  • Travel · 2019-05-14 · $25
  • Travel · 2019-05-14 · $41
AbbVieMavyret$8,454
11 payments
  • Consulting for Mavyret · 2019-12-19 · $3,000
  • Consulting for Mavyret · 2019-09-19 · $1,200
  • Travel for Mavyret · 2019-06-27 · $42
  • Consulting for Mavyret · 2019-06-27 · $3,000
  • Meals for Mavyret · 2019-06-09 · $56
  • Meals for Mavyret · 2019-06-09 · $47
  • Meals for Mavyret · 2019-06-09 · $30
  • Meals for Mavyret · 2019-06-09 · $30
  • Travel for Mavyret · 2019-06-09 · $576
  • Travel for Mavyret · 2019-06-08 · $183
  • Travel for Mavyret · 2019-06-08 · $289
Gilead SciencesEpclusa$5,711
5 payments
  • Consulting · 2019-12-10 · $357
  • Consulting · 2019-10-24 · $1,430
  • Consulting for Epclusa · 2019-04-13 · $1,340
  • Meals · 2019-04-13 · $84
  • Consulting · 2019-01-16 · $2,500
Mallinckrodt EnterprisesNone$4,649
4 payments
  • Meals · 2019-05-17 · $130
  • Consulting · 2019-05-17 · $3,850
  • Travel · 2019-05-17 · $309
  • Travel · 2019-05-17 · $360
Merck Sharp & DohmeV934$2,546
2 payments
  • Consulting for V934 · 2019-08-08 · $2,500
  • Meals · 2019-04-11 · $46
EisaiLenvima$2,082
4 payments
  • Consulting for Lenvima · 2019-02-15 · $1,875
  • Travel for Lenvima · 2019-01-17 · $61
  • Travel for Lenvima · 2019-01-17 · $64
  • Meals for Lenvima · 2019-01-17 · $83
AllerganNone$165
1 payment
  • Meals · 2019-05-19 · $165
La Jolla PharmaceuticalNone$42
1 payment
  • Meals · 2019-05-17 · $42

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Eiger BioPharmaceuticals, Inc. · D-Livr · 2022Their institution$128,375
Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2025Their institution$117,201
Takeda Pharmaceuticals U.S.A., Inc. · Hepatic Impairment · 2024Their institution$109,596
Allergan, Inc. · Aurora: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2020Their institution$100,088
Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2024Their institution$88,400
Ultragenyx Pharmaceutical Inc. · Ux701-Cl301 · 2024Their institution$72,818
EIGER BIOPHARMACEUTICALS, INC. · Limt-2 · 2023Their institution$68,717
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2020Their institution$51,087
Madrigal Pharmaceuticals · A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis To Resolve Nash and Reduce Progression To Cirrhosis Andor Hepatic Decompensation · 2025Their institution$44,509
Ultragenyx Pharmaceutical Inc. · Ux701-Cl301 · 2025Their institution$39,823
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and He · 2024Their institution$38,169
Takeda Pharmaceuticals U.S.A., Inc. · Hepatic Impairment · 2025Their institution$37,710
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebocontrolled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj73763989 + Nucleos(T)Ide Analog in Participants Coinfected With Hepatitis B and Hepatitis D Virus · 2022Their institution$36,274
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2020Their institution$33,944
Allergan Inc. · Aurora A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2019Their institution$31,149
Gilead Sciences, Inc. · A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis · 2021Their institution$30,223
Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2024Their institution$28,890
EIGER BIOPHARMACEUTICALS, INC. · D-Livr · 2023Their institution$26,981
E.R. Squibb & Sons, L.L.C. · Phase Iib in Nash Mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study To Evaluate the Efficacy and Safety of Bms-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (Nash) · 2023Their institution$26,217
Ultragenyx Pharmaceutical Inc. · Ux701-Cl301 · 2022Their institution$24,972
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebocontrolled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj73763989 + Nucleos(T)Ide Analog in Participants Coinfected With Hepatitis B and Hepatitis D Virus · 2023Their institution$22,517
Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2025Their institution$21,719
AbbVie Inc. · 2020Their institution$20,530
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis · 2019Their institution$19,430
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and He · 2023Their institution$16,561
Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2021Their institution$13,696
AbbVie, Inc. · 2019Their institution$13,641
Allergan, Inc. · Aurora: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2021Their institution$13,351
Takeda Pharmaceuticals U.S.A., Inc. · Tak-999-3002 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With Metavir Stage F1 Fibrosis · 2025Their institution$9,407
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2021Their institution$8,765
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and He · 2025Their institution$8,382
E.R. Squibb & Sons, L.L.C. · Safety and Effectiveness of Bms-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (Nash) · 2024Their institution$7,610
Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2020Their institution$7,140
Gilead Sciences, Inc. · A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis · 2019Their institution$5,336
Allergan, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. · 2020Their institution$5,195
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus · 2023Their institution$3,864
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2022Their institution$3,816
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis · 2019Their institution$3,790
La Jolla Pharmaceutical Company · A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With Ljpc-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis · 2020Their institution$3,302
Gilead Sciences, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, Gs-0976, Gs-9674, and Combinations in Subjects With Bridging (F3) Fibrosis Or Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (Nash) · 2019Their institution$3,200
Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B · 2025Their institution$2,932
La Jolla Pharmaceutical Company · A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With Ljpc-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis · 2019Their institution$2,880
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2022Their institution$2,534
ABBVIE INC. · An Open-Label, Multicenter Study To Evaluate Long-Term Outcomes With Abt-450/Ritonavir/Abt-267 (Abt-450/R/Abt-267) and Abt-333 With Or Without Ribavirin (Rbv) in Adults With Genotype 1 Chronic Hepatitis C Virus (Hcv) Infection (Topaz II) · 2021Their institution$2,496
Allergan Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. · 2019Their institution$2,221
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2023Their institution$922
E.R. Squibb & Sons, L.L.C. · Phase Iib in Nash Mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study To Evaluate the Efficacy and Safety of Bms-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (Nash) · 2022Their institution$903
EIGER BIOPHARMACEUTICALS, INC. · D-Livr · 2022Their institution$900
Allergan, Inc. · Aurora: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2022Their institution$750
E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2021Their institution$709
Merck Sharp & Dohme Corporation · A Phase III Double Blind Clinical Trial To Study the Efficacy and Safety of the Combination Regimen of Mk-5172 and Mk-8742 in Subjects With Chronic Hcv Gt1, Gt4 and Gt6 Infection With Inherited Blood Disorders With and Without Hiv Co-Infection · 2021Their institution$337
Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2022Their institution$232
MACROGENICS, INC. · Limt-2 · 2024Their institution$96
Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2019Their institution$60
Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2023Their institution$60
E.R. Squibb & Sons, L.L.C. · Phase Iib Study - F3 24 Wk · 2020Their institution$40
E.R. Squibb & Sons, L.L.C. · Phase Iib Study - F4 48 Wk · 2020Their institution$38

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1578527008
Licence
CA G145613, IN 01043753California G145613: Current · expires 2027-12-31
Trained
Wayne State University School of Medicine, 1988
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
IN 200034940
Taxonomy
Federal specialty code 207RI0008X (207RI0008X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RT0003X (207RT0003X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-04-13
NPI last updated
2026-09-03
NPI record certified
2026-09-03

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 1804 Embarcadero Rd, Palo Alto, CA, 94303